WallStreetZenWallStreetZen

NASDAQ: IMA
Imagenebio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMA

Based on 2 analysts offering 12 month price targets for Imagenebio Inc

Min Forecast
$2.00-60%
Avg Forecast
$15.00+200%
Max Forecast
$28.00+460%

Should I buy or sell IMA stock?

Based on 2 analysts offering ratings for Imagenebio Inc.

Hold
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
1 analysts 50%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IMA stock forecasts and price targets.

IMA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-21
lockedlocked$00.00+00.00%2026-05-11

1 of 1

Forecast return on equity

Is IMA forecast to generate an efficient return?

Company
-38.33%
Industry
19.68%
Market
168.87%
IMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMA forecast to generate an efficient return on assets?

Company
-35.82%
Industry
23.53%
IMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMA earnings per share forecast

What is IMA's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$3.25
Avg 2 year Forecast
-$3.51
Avg 3 year Forecast
-$3.79

IMA revenue forecast

What is IMA's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

IMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMA$5.00$15.00+200.00%Hold
HYPD$3.64$9.83+169.92%Strong Buy
EXOZ$6.28N/AN/A
XLO$8.93N/AN/A
FRMM$4.46$9.00+101.79%Buy
View Top Biotech Stocks

Imagenebio Stock Forecast FAQ

Is Imagenebio Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: IMA) stock is to Hold IMA stock.

Out of 2 analysts, 0 (0%) are recommending IMA as a Strong Buy, 1 (50%) are recommending IMA as a Buy, 0 (0%) are recommending IMA as a Hold, 1 (50%) are recommending IMA as a Sell, and 0 (0%) are recommending IMA as a Strong Sell.

If you're new to stock investing, here's how to buy Imagenebio stock.

What is IMA's earnings growth forecast for 2026-2028?

(NASDAQ: IMA) Imagenebio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.19%.

Imagenebio's earnings in 2026 is -$53,330,000.On average, 5 Wall Street analysts forecast IMA's earnings for 2026 to be -$36,917,205, with the lowest IMA earnings forecast at -$39,714,204, and the highest IMA earnings forecast at -$35,161,135. On average, 5 Wall Street analysts forecast IMA's earnings for 2027 to be -$39,869,719, with the lowest IMA earnings forecast at -$60,961,859, and the highest IMA earnings forecast at -$11,680,648.

In 2028, IMA is forecast to generate -$42,993,640 in earnings, with the lowest earnings forecast at -$56,400,844 and the highest earnings forecast at -$8,581,701.

What is IMA's revenue growth forecast for 2026-2028?

(NASDAQ: IMA) Imagenebio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.

Imagenebio's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast IMA's revenue for 2026 to be $0, with the lowest IMA revenue forecast at $0, and the highest IMA revenue forecast at $0. On average, 4 Wall Street analysts forecast IMA's revenue for 2027 to be $0, with the lowest IMA revenue forecast at $0, and the highest IMA revenue forecast at $0.

In 2028, IMA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is IMA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IMA) forecast ROA is -35.82%, which is lower than the forecast US Biotechnology industry average of 23.53%.

What is IMA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year IMA price target, the average IMA price target is $15.00, with the highest IMA stock price forecast at $28.00 and the lowest IMA stock price forecast at $2.00.

On average, Wall Street analysts predict that Imagenebio's share price could reach $15.00 by Aug 21, 2027. The average Imagenebio stock price prediction forecasts a potential upside of 200% from the current IMA share price of $5.00.

What is IMA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IMA) Imagenebio's current Earnings Per Share (EPS) is -$4.15. On average, analysts forecast that IMA's EPS will be -$3.25 for 2026, with the lowest EPS forecast at -$3.50, and the highest EPS forecast at -$3.10. On average, analysts forecast that IMA's EPS will be -$3.51 for 2027, with the lowest EPS forecast at -$5.37, and the highest EPS forecast at -$1.03. In 2028, IMA's EPS is forecast to hit -$3.79 (min: -$4.97, max: -$0.76).

What is IMA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IMA) forecast ROE is -38.33%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.